Akeso's Ivonescimab Outperforms Pembrolizumab in NSCLC Survival Study — Akeso, Inc.

Event summary

Akeso's ivonescimab demonstrated a 27% reduction in the risk of death compared to pembrolizumab in PD-L1-positive NSCLC patients.
Median overall survival was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab.
The study included 45.5% squamous NSCLC patients, traditionally high-risk for anti-VEGF therapies, with no significant bleeding risk observed.
Ivonescimab showed particularly strong benefits in the PD-L1 TPS ≥50% subgroup, with median OS not reached.
The HARMONi-2 study is the first Phase III trial to show statistically significant OS and PFS benefits versus pembrolizumab.

The big picture

Akeso's positive Phase III results for ivonescimab position the drug as a potential challenger to pembrolizumab in the first-line treatment of PD-L1-positive NSCLC. The study's success in high-risk squamous patients and across PD-L1 expression levels suggests broad applicability. With an expanding pipeline of over 50 innovative assets, Akeso is solidifying its position as a competitive player in the biopharmaceutical industry.

What we're watching

Regulatory Pathway: Whether Akeso can secure international approvals for ivonescimab based on these Phase III results.
Market Positioning: How ivonescimab's dual immuno-oncology + anti-angiogenesis mechanism will compete against established PD-1/L1 therapies.
Pipeline Expansion: The pace at which Akeso advances ivonescimab into other major solid tumors beyond lung cancer.